Sugi Predict

Sugi Predict / Targets / STRADA

STRADA

STE20-related kinase adapter protein alpha · Q7RTN6 · STRADA on Sugi Atlas →

1,990 patent compounds predicted against STRADA, 1,421 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Azd-1480 Azd-1480 (SCHEMBL219103) 1.00 1/20
Azd-1480 Azd-1480 (SCHEMBL220400) 1.00 1/20
Brivanib Brivanib (SCHEMBL1227111) 1.00 1/20
Brivanib Brivanib (SCHEMBL1227112) 1.00 1/20
Brivanib Brivanib (SCHEMBL1227589) 1.00 1/20
Ph-797804 Ph-797804 (SCHEMBL2015676) 1.00 1/20
Azd-1480 Azd-1480 (SCHEMBL3345019) 1.00 1/20
SCHEMBL4376166 SCHEMBL4376166 0.88 1/20
SCHEMBL4378769 SCHEMBL4378769 0.85 1/20
SCHEMBL4381593 SCHEMBL4381593 0.85 1/20
SCHEMBL1226392 SCHEMBL1226392 0.84 1/20
SCHEMBL3450913 SCHEMBL3450913 0.84 1/20
SCHEMBL3451591 SCHEMBL3451591 0.84 1/20
SCHEMBL1227534 SCHEMBL1227534 0.83 1/20
SCHEMBL4374739 SCHEMBL4374739 0.82 1/20
SCHEMBL1226332 SCHEMBL1226332 0.82 1/20
SCHEMBL1227523 SCHEMBL1227523 0.82 1/20
SCHEMBL1227542 SCHEMBL1227542 0.82 1/20
SCHEMBL2707623 SCHEMBL2707623 0.82 1/20
SCHEMBL4377493 SCHEMBL4377493 0.82 1/20

Clinical trials — most relevant to STRADA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF PHASE3COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive PHASE2COMPLETED
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE PHASE1RECRUITING
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia PHASE1COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery EARLY_PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Immune Cell Response to Stimuli nanRECRUITING
New Genes in the Carcinogenesis of Colorectal Cancer nanUNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib nanCOMPLETED
Limb RIPC in Patients Undergoing Lung Lobectomy. Study of Oxidative Lung Damage nanCOMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a STRADA binder may also engage these)

ProteinNameSimilarity
Q3UUJ4 — 0.999 Q3UUJ4 →
Q5RBJ6 — 0.999 Q5RBJ6 →
Q4R6X5 — 0.998 Q4R6X5 →
Q7TNZ6 — 0.996 Q7TNZ6 →
Q5E9J9 — 0.993 Q5E9J9 →
Q5ZK47 — 0.991 Q5ZK47 →
Q9C0K7 — 0.986 Q9C0K7 →
Q8K4T3 — 0.981 Q8K4T3 →
O54785 — 0.979 O54785 →
PLK2 Serine/threonine-protein kinase PLK2 0.977 landscape →
P09560 — 0.977 P09560 →
Q61084 — 0.976 Q61084 →
Q5R4L1 — 0.976 Q5R4L1 →
MAP3K3 Mitogen-activated protein kinase kinase kinase 3 0.976 landscape →
Q61083 — 0.976 Q61083 →
Q5R5M7 — 0.976 Q5R5M7 →
Q28GW8 — 0.976 Q28GW8 →
LIMK2 LIM domain kinase 2 0.976 landscape →
Q9R012 — 0.975 Q9R012 →
A7E3S4 — 0.975 A7E3S4 →
P11345 — 0.975 P11345 →
Q91821 — 0.975 Q91821 →
EIF2AK4 eIF-2-alpha kinase GCN2 0.974 landscape →
P53351 — 0.974 P53351 →
MELK Maternal embryonic leucine zipper kinase 0.974 landscape →
RAF1 RAF proto-oncogene serine/threonine-protein kinase 0.973 landscape →
Q6PJI9 — 0.973 Q6PJI9 →
P62205 — 0.973 P62205 →
Q99N57 — 0.973 Q99N57 →
Q9WVS7 — 0.973 Q9WVS7 →